FDA 483 - Nostrum Laboratories Inc - April 21, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Nostrum Laboratories Inc, a drug manufacturer in Kansas City, MO, revealed significant deficiencies in their quality system. The firm failed to adequately investigate product complaints for low bottle counts and did not extend investigations to other potentially affected batches. Additionally, the inspection found a systemic failure to follow written procedures for internal and external audits, vendor qualification, and corrective and preventive actions (CAPA).
ID · 297a9276-a98b-46ac-a777-a80a252c0fe6